 |
49 Diseases |  |
64 Trials |
|
64 Trials |  |
670 News |  |
| «1234567891011 |
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 21, 2014
P3, N=242, Active, not recruiting, Sponsor: Children's Oncology Group
N=315 --> 242
- |||| leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Trial primary completion date: AALL0232: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 8, 2014
P3, N=3154, Active, not recruiting, Sponsor: Children's Oncology Group
N=315 --> 242 Trial primary completion date: Oct 2012 --> Jun 2014
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment closed: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 1, 2014
P3, N=1900, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2012 --> Jun 2014 Recruiting --> Active, not recruiting
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial, Combination therapy: NCI-2014-01707: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 24, 2014
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 1, 2014
P3, N=315, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
New P3 trial: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - Jun 19, 2014
P3, N=600, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- prednisone delayed-release tablet / Generic mfg.
Trial primary completion date, Metastases: Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis (clinicaltrials.gov) - Jun 13, 2014
P1, N=10, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2012 --> Apr 2013
- Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 19, 2014
P2, N=50, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || Trial primary completion date: AHOD03P1: Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease (clinicaltrials.gov) - May 11, 2014
P=N/A, N=188, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2012 --> Apr 2013 Trial primary completion date: Sep 2013 --> Nov 2012
- | prednisone delayed-release tablet / Generic mfg.
Trial termination: A Study Assessing the Efficacy and Safety of Lodotra (clinicaltrials.gov) - Mar 31, 2014
P3, N=62, Terminated, Sponsor: Mundipharma Research Limited
Trial primary completion date: Sep 2013 --> Nov 2012 Active, not recruiting --> Terminated
- | prednisone delayed-release tablet / Generic mfg.
Enrollment change: A Study Assessing the Efficacy and Safety of Lodotra (clinicaltrials.gov) - Mar 31, 2014
P3, N=62, Terminated, Sponsor: Mundipharma Research Limited
Active, not recruiting --> Terminated N=471 --> 62
- peripheral blood stem cell transplantation / National Cancer Institute
Clinical: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 18, 2014
P2, N=85, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=471 --> 62 Recruiting --> Active, not recruiting
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment change: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 17, 2014
P3, N=1900, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=1580 --> 1900
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy, Metastases: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 4, 2014
P1/2, N=95, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=1580 --> 1900 Recruiting --> Active, not recruiting
- || Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci, Oncaspar liquid (pegaspargase) / Servier
Enrollment change: AALL07P4: Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 26, 2014
P=N/A, N=166, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting N=318 --> 166
- || Enrollment change: AHOD03P1: Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=188, Active, not recruiting, Sponsor: Children's Oncology Group
N=318 --> 166 N=150 --> 188
- | prednisone delayed-release tablet / Generic mfg.
New P4 trial: Efficacy of Lodotra (clinicaltrials.gov) - Feb 24, 2014
P4, N=137, Recruiting, Sponsor: Mundipharma Korea Ltd
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 5, 2014
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
N=150 --> 188 Not yet recruiting --> Recruiting
- | melphalan / Generic mfg., lenalidomide / Generic mfg., thalidomide / Generic mfg.
Enrollment closed: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Dec 8, 2013
P3, N=304, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 4, 2013
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Aug 29, 2013
P2, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | alisertib (MLN8237) / Puma
Trial initiation date, Combination therapy: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 11, 2013
P1/2, N=43, Recruiting, Sponsor: Thomas Jefferson University
Not yet recruiting --> Recruiting Initiation date: May 2013 --> Aug 2013
- | alisertib (MLN8237) / Puma
Enrollment open, Combination therapy: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 11, 2013
P1/2, N=43, Recruiting, Sponsor: Thomas Jefferson University
Initiation date: May 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- ||||| cyclophosphamide / Generic mfg.
Enrollment closed: Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma (clinicaltrials.gov) - Jun 10, 2013
P3, N=53, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche
New P2 trial: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - May 15, 2013
P2, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
- prednisone delayed-release tablet / Generic mfg.
Enrollment closed, Metastases: Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis (clinicaltrials.gov) - May 13, 2013
P1, N=10, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | alisertib (MLN8237) / Puma
New P1/2 trial, Combination therapy: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - May 5, 2013
P1/2, N=43, Recruiting, Sponsor: Thomas Jefferson University
- || prednisone delayed-release tablet / Generic mfg.
New P3 trial: A Study Assessing the Efficacy and Safety of Lodotra (clinicaltrials.gov) - Mar 27, 2013
P3, N=62, Terminated, Sponsor: Mundipharma Research Limited
- || Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci, Oncaspar liquid (pegaspargase) / Servier
Enrollment closed: AALL07P4: Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 13, 2013
P=N/A, N=166, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- ||||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
New P2 trial, Combination therapy: NCI-2018-01856: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov) - Feb 5, 2013
P2, N=200, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 20, 2012
P3, N=195, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Completed --> Active, not recruiting
- ||| apatorsen (OGX-427) / Achieve Life Sciences
Enrollment closed, Metastases: OGX-427 in Castration Resistant Prostate Cancer Patients (clinicaltrials.gov) - Aug 9, 2012
P2, N=72, Active, not recruiting, Sponsor: British Columbia Cancer Agency
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- || Oncaspar liquid (pegaspargase) / Servier
Enrollment closed: AALL08P1: Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) (clinicaltrials.gov) - Jul 18, 2012
P=N/A, N=165, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- ||||| leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Enrollment closed: AALL0232: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 17, 2012
P3, N=3154, Active, not recruiting, Sponsor: Children's Oncology Group
Suspended --> Active, not recruiting Suspended --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial completion: A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis. (clinicaltrials.gov) - Jul 15, 2012
P2/3, N=50, Completed, Sponsor: University of South Florida
Suspended --> Active, not recruiting Recruiting --> Completed
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 2, 2012
P3, N=315, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed N=244 --> 315
- | veliparib (ABT-888) / AbbVie, Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
New P2 trial, PARP Biomarker, Metastases: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Apr 10, 2012
P2, N=148, Recruiting, Sponsor: National Cancer Institute (NCI)
N=244 --> 315 .
- Enrollment closed: Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 10, 2012
P2, N=80, Active, not recruiting, Sponsor: Stanford University
. Recruiting --> Active, not recruiting
- || Enrollment change, HEOR: Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone) (clinicaltrials.gov) - Oct 3, 2011
P=N/A, N=2728, Completed, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting N=8000 --> 2728
- ||| Trial completion, HEOR: Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone) (clinicaltrials.gov) - Oct 3, 2011
P=N/A, N=2728, Completed, Sponsor: Merck KGaA
N=8000 --> 2728 Active, not recruiting --> Completed